KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC

Opinion
Video

Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.

Related Videos
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Kian-Huat Lim, MD, PhD
Jonathan E. Rosenberg, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Benjamin Garmezy, MD
Video 16 - "Neoadjuvant Approach in RAI-R-DTC"
Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"
A panel of 5 experts on lung cancer